1. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines.;Dooling;MMWR Morb Mortal Wkly Rep,2018
2. Food and Drug Administration. FDA briefing document: Shingrix (zoster vaccine recombinant, adjuvanted). Presented at the Vaccines and Related Biological Products Advisory Committee meeting, Silver Spring, MD; September 13, 2017.https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM575190.pdf
3. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).;Shimabukuro;Vaccine,2015
4. Kohl KS, Bonhoeffer J, Braun MM, The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in patient safety: from research to implementation (volume 2: concepts and methodology). Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2005. https://www.ncbi.nlm.nih.gov/books/NBK20507/
5. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000–2013.;Hibbs;Vaccine,2015